Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Merck and Daiichi Sankyo's Lung Cancer Drug Shows Promise in Pivotal Trial

Merck and Daiichi Sankyo have reported encouraging results from a pivotal Phase II trial of their antibody-drug conjugate (ADC) ifinatamab deruxtecan (I-DXd) in patients with extensive-stage small cell lung cancer. The data, presented at the 2025 World Conference on Lung Cancer, demonstrate a significant response rate and could pave the way for accelerated approval.

NoahAI News9/9/2025

Pfizer and BioNTech Report Positive Data for Updated COVID-19 Booster Amid Changing Vaccine Landscape

Pharmaceutical giants Pfizer and BioNTech have announced encouraging results from their latest clinical trial of an updated COVID-19 booster shot, demonstrating strong immune responses against currently circulating coronavirus strains. This development comes at a time of significant shifts in U.S. vaccine policy and ongoing debates about the future of mRNA vaccine technology.

NoahAI News9/9/2025

Summit's Lung Cancer Drug Ivonescimab Faces Setback in Phase 3 Trial

Summit Therapeutics and Akeso's experimental lung cancer drug ivonescimab has encountered a significant obstacle in its path to regulatory approval. The latest data from the global Phase 3 Harmoni trial, presented at the World Conference on Lung Cancer in Spain, revealed that the combination of ivonescimab and chemotherapy failed to extend overall survival compared to chemotherapy alone in patients with lung cancer.

NoahAI News9/9/2025

FDA Clears Microbot Medical's Remote-Controlled Catheter System, Marking Milestone in Endovascular Robotics

Microbot Medical has achieved a significant breakthrough in endovascular robotics with the FDA's 510(k) clearance of its Liberty system, a remote-controlled robot designed for minimally invasive procedures. This innovative technology promises to revolutionize catheter-based interventions by allowing clinicians to operate outside the radiation field of the catheterization laboratory.

NoahAI News9/9/2025

Eli Lilly's Jaypirca Shows Promise in First-Line CLL Treatment

Eli Lilly's Bruton tyrosine kinase (BTK) inhibitor Jaypirca (pirtobrutinib) has demonstrated significant potential as a first-line treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), marking a major advancement in blood cancer therapy.

NoahAI News9/9/2025

FDA Rejection of Saol's Ultra-Rare Disease Treatment Sparks Industry Debate

The pharmaceutical industry is grappling with the implications of the FDA's recent rejection of Saol Therapeutics' investigational treatment for pyruvate dehydrogenase complex deficiency (PDCD), an ultra-rare pediatric mitochondrial disease. The decision has ignited discussions about regulatory flexibility in rare disease drug approvals and prompted calls for congressional intervention.

NoahAI News9/9/2025

UK Biotech NRG Therapeutics Secures £50 Million for Neurodegenerative Disease Drug Development

British biotechnology company NRG Therapeutics has successfully raised £50 million (approximately $67 million) in a Series B funding round to advance its innovative approach to treating neurodegenerative disorders. The company's lead experimental medicine, targeting mitochondrial dysfunction in conditions such as Parkinson's disease and amyotrophic lateral sclerosis (ALS), is now set to enter clinical testing by early 2026.

NoahAI News9/9/2025

Chinese Surgical Robotics Firm Ronovo Secures $67M in Series D Funding, Partners with Johnson & Johnson

Ronovo Surgical, a Shanghai-based surgical robotics company, has successfully closed a $67 million Series D financing round led by Johnson & Johnson Development Corporation (JJDC), the venture capital arm of Johnson & Johnson. This latest investment brings Ronovo's total funding to over $100 million in the past year, following previous rounds that included a $44 million Series B in 2024 and more than $50 million in earlier financing.

NoahAI News9/9/2025

Senseonics Takes Control of Eversense CGM Commercialization, Aims for Market Expansion

Senseonics, a leader in implantable continuous glucose monitoring (CGM) technology, has announced a strategic shift in its commercial operations, opting to bring the distribution and marketing of its Eversense CGM systems back in-house. This move marks a significant change in the company's approach to market penetration and signals confidence in the potential of its latest long-term CGM implant.

NoahAI News9/9/2025

Regeneron's Allergen-Blocking Antibodies Show Promise in Phase 3 Trials

Regeneron Pharmaceuticals has reported positive results from two phase 3 clinical trials evaluating novel allergen-blocking antibodies for cat and birch pollen allergies. The studies demonstrate significant reductions in allergy symptoms, potentially offering a new approach to allergy treatment that could replace traditional immunotherapy methods.

NoahAI News9/9/2025

Dianthus Therapeutics Advances gMG Treatment with Promising Phase 2 Results

Dianthus Therapeutics has made significant strides in the competitive generalized myasthenia gravis (gMG) market, announcing positive results from its phase 2 trial of claseprubart. The company is now gearing up for a pivotal phase 3 study, positioning itself as a potential challenger to established treatments in the autoimmune disease space.

NoahAI News9/9/2025

Strive Health Secures $550M Investment to Revolutionize Kidney Care with AI and Multi-Specialty Services

Strive Health, a leader in value-based kidney care, has announced a substantial $550 million investment to expand its artificial intelligence capabilities and grow its multi-specialty services. The funding, comprising a $300 million series D equity round and $250 million in debt financing, marks a significant milestone in the company's mission to transform kidney care delivery and management.

NoahAI News9/9/2025

«1...64 65 66 67 »